UNSPSC 51432100: Antihypertensive guanidines

Antihypertensive drugs made from a family of iminourea derivatives.

UNSPSC 51432100 Antihypertensive guanidines, a Class code, covers emergency and institutional pharmaceutical procurement where state and local governments acquire specific medications including guanidine-class antihypertensives for use by fire rescue services, health agencies, and multistate purchasing coalitions. Recent solicitations show state and local buyers acquiring individual vial and injection units of branded and generic antihypertensives—notably labetalol, diltiazem, and adenosine—alongside broader pharmaceutical product categories through cooperative purchasing agreements. Issuing bodies span municipal fire departments (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), with MMCAP sourcing on behalf of multiple state and local member facilities across jurisdictions including Minnesota and Oregon. The code's practical scope extends beyond guanidines alone to encompass emergency medication procurement bundles and generic pharmaceutical supply contracts where antihypertensives represent line items within larger medication portfolios.

Geographic activity centers on the South (Florida), Southwest (Texas), and Upper Midwest (Minnesota), with multistate cooperative mechanisms expanding coverage to Pacific Northwest jurisdictions. Representative opportunities include the City of Tampa's sealed-bid procurement (26P00188) for Advanced Life Support Medications due April 8, 2026, requesting 1,020 units of Diltiazem 25mg vials among four medication line items for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year term with two optional renewals; the Texas Health and Human Services Commission's Request for Information (HHS0017013) posted April 3, 2026, exploring direct-to-manufacturer prescription program capabilities as preliminary market intelligence; and MMCAP's Request for Proposal (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with products effective July 1, 2026, requiring vendor compliance with cGMP, DSCSA, and a 3 percent administrative fee structure across two-year terms. Activity shows steady municipal, state, and cooperative procurement rhythm with performance guarantees, expiration-date requirements (nine months to one year minimum), and insurance mandates.